Bioscience Industry Recommends Revisions to the Clinical Trials Directive
Bioscience Industry Recommends Revisions to the Clinical Trials Directive
LONDON, UK, October 3, 2007-The BioIndustry Association (BIA) today expressed its support for a revision of the Clinical Trials Directive 2001/20/EC at the European Commission-EMEA Conference on the operation of the Clinical Trials Directive. The conference offered stakeholder representatives a platform to provide feedback on the implementation of the Clinical Trials Directive and offer recommendations for the future.
The BIA believes that the Clinical Trials Directive should be reviewed in order to achieve harmonisation, transparency, and consistency in the approval and conduct of clinical trials across EU Member States, whilst ensuring public health protection. This will facilitate efficient development of biopharmaceutical products in Europe, which would in turn have a direct benefit of improving patient access to innovative medicines. It should be emphasised that the entire Directive does not need to be repealed and replaced by a different legal instrument.
The BIA, working EuropaBio, the European association for the bioscience industry, has identified five key areas for improving the Clinical Trials Directive:
- It is necessary to modify the language used to reduce the flexibility of the provisions in the Directive. Currently, the provisions are open to misinterpretation and misapplication of the law by Member States.
- The current regulatory and ethics review processes should be streamlined to accelerate the initiation of trials and allow patients faster access to innovative treatments.
- The roles and scope of responsibilities of National Competent Authorities (NCAs) and Ethics Committees need to be more clearly defined.
- Mutual recognition of assessments carried out by NCAs should be introduced.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
